|
1
|
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.
|
Comput Methods Programs Biomed
|
2001
|
1.57
|
|
2
|
Role of modelling and simulation in Phase I drug development.
|
Eur J Pharm Sci
|
2001
|
1.33
|
|
3
|
Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.
|
J Pharmacokinet Biopharm
|
1998
|
1.33
|
|
4
|
Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.
|
Clin Microbiol Infect
|
2011
|
1.18
|
|
5
|
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
|
Clin Pharmacol Ther
|
2012
|
1.08
|
|
6
|
Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.
|
Anticancer Res
|
1995
|
1.08
|
|
7
|
Optimal design of a population pharmacodynamic experiment for ivabradine.
|
Pharm Res
|
2001
|
1.05
|
|
8
|
Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients.
|
Clin Infect Dis
|
2000
|
1.02
|
|
9
|
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
|
Br J Clin Pharmacol
|
2007
|
0.98
|
|
10
|
Evaluation of tests based on individual versus population modeling to compare dissolution curves.
|
J Biopharm Stat
|
2001
|
0.97
|
|
11
|
Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
|
Antimicrob Agents Chemother
|
2009
|
0.95
|
|
12
|
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
|
Br J Clin Pharmacol
|
2005
|
0.92
|
|
13
|
Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.
|
Br J Clin Pharmacol
|
1994
|
0.91
|
|
14
|
Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.
|
J Pharmacokinet Biopharm
|
1988
|
0.89
|
|
15
|
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
|
HIV Med
|
2004
|
0.88
|
|
16
|
A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients.
|
Cancer Chemother Pharmacol
|
1991
|
0.88
|
|
17
|
Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.
|
Eur J Clin Pharmacol
|
2003
|
0.87
|
|
18
|
Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
|
J Pharmacokinet Biopharm
|
1995
|
0.87
|
|
19
|
Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics.
|
Math Biosci
|
1997
|
0.86
|
|
20
|
Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method.
|
Br J Clin Pharmacol
|
1997
|
0.86
|
|
21
|
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
|
Eur J Clin Pharmacol
|
2014
|
0.85
|
|
22
|
Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?
|
Br J Cancer
|
2013
|
0.85
|
|
23
|
Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake.
|
Stat Med
|
1994
|
0.84
|
|
24
|
Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.
|
J Pharmacokinet Biopharm
|
1998
|
0.83
|
|
25
|
Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits.
|
J Pharm Sci
|
2000
|
0.83
|
|
26
|
Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.
|
Antimicrob Agents Chemother
|
2011
|
0.83
|
|
27
|
Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
|
Clin Microbiol Infect
|
2012
|
0.81
|
|
28
|
Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses.
|
Clin Microbiol Infect
|
2014
|
0.80
|
|
29
|
Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR.
|
J Control Release
|
1999
|
0.79
|
|
30
|
Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.
|
J Pharmacokinet Biopharm
|
1999
|
0.78
|
|
31
|
Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study.
|
Eur Respir J
|
2012
|
0.78
|
|
32
|
Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.
|
Clin Pharmacol Ther
|
2011
|
0.77
|
|
33
|
Prediction of fluindione maintenance dosage hampered by large intraindividual variability.
|
Ther Drug Monit
|
2000
|
0.77
|
|
34
|
Modeling INR data to predict maintenance fluindione dosage.
|
Ther Drug Monit
|
1998
|
0.77
|
|
35
|
Plasma concentrations of zidovudine.
|
N Engl J Med
|
1992
|
0.76
|
|
36
|
Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography.
|
J Chromatogr B Biomed Sci Appl
|
1998
|
0.76
|
|
37
|
Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach.
|
Ther Drug Monit
|
1994
|
0.76
|
|
38
|
Best practices in population modeling should always be evolving.
|
CPT Pharmacometrics Syst Pharmacol
|
2013
|
0.76
|
|
39
|
Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.
|
CPT Pharmacometrics Syst Pharmacol
|
2013
|
0.76
|
|
40
|
Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software.
|
Eur J Clin Pharmacol
|
1994
|
0.76
|
|
41
|
Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.
|
Clin Pharmacol Ther
|
2012
|
0.75
|
|
42
|
Computer-assisted individual estimation of radioiodine thyroid uptake in Grave's disease.
|
Comput Methods Programs Biomed
|
1993
|
0.75
|
|
43
|
The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.
|
Antimicrob Agents Chemother
|
2014
|
0.75
|
|
44
|
Assessment of the global two-stage method to EC50 determination.
|
J Pharmacol Toxicol Methods
|
1998
|
0.75
|
|
45
|
New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research.
|
Eur J Clin Pharmacol
|
1993
|
0.75
|
|
46
|
Assessment of salivary amylase as a stress biomarker in pregnant patients.
|
Int J Obstet Anesth
|
2011
|
0.75
|
|
47
|
[Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. A randomized trial (FFAACS)].
|
Therapie
|
2001
|
0.75
|
|
48
|
Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone.
|
Cardiovasc Drugs Ther
|
1990
|
0.75
|